“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Opinion|Videos|February 7, 2025 (Updated: January 31, 2025)
Role of Bridging Therapy for CAR-T Patients
This segment discusses the process and critical importance of bridging strategies for patients awaiting CAR T-cell therapy.
Advertisement
Video content above is prompted by the following:
- Please comment on the process and importance of bridging patients for CAR T-cell therapy.
Advertisement
Related to this article
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
3
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
4
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
5